[go: up one dir, main page]

AU2002220517A1 - 3-substituted quinuclidines and their use as nicotinic agonists - Google Patents

3-substituted quinuclidines and their use as nicotinic agonists

Info

Publication number
AU2002220517A1
AU2002220517A1 AU2002220517A AU2051702A AU2002220517A1 AU 2002220517 A1 AU2002220517 A1 AU 2002220517A1 AU 2002220517 A AU2002220517 A AU 2002220517A AU 2051702 A AU2051702 A AU 2051702A AU 2002220517 A1 AU2002220517 A1 AU 2002220517A1
Authority
AU
Australia
Prior art keywords
diseases
disorders
nervous system
disorders related
cholinergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220517A
Inventor
Philip K. Ahring
Tino Dyhring Jorgensen
Elsebet Ostergaard Nielsen
Gunnar M. Olsen
Dan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2002220517A1 publication Critical patent/AU2002220517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
AU2002220517A 2000-12-01 2001-11-28 3-substituted quinuclidines and their use as nicotinic agonists Abandoned AU2002220517A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001813 2000-12-01
DKPA200001813 2000-12-01
DKPA200100352 2001-03-05
DKPA200100352 2001-03-05
PCT/DK2001/000791 WO2002044176A1 (en) 2000-12-01 2001-11-28 3-substituted quinuclidines and their use as nicotinic agonists

Publications (1)

Publication Number Publication Date
AU2002220517A1 true AU2002220517A1 (en) 2002-06-11

Family

ID=26068919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220517A Abandoned AU2002220517A1 (en) 2000-12-01 2001-11-28 3-substituted quinuclidines and their use as nicotinic agonists

Country Status (7)

Country Link
US (1) US6884807B2 (en)
EP (1) EP1339712B1 (en)
JP (1) JP2004514722A (en)
AT (1) ATE385497T1 (en)
AU (1) AU2002220517A1 (en)
DE (1) DE60132710T2 (en)
WO (1) WO2002044176A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
DE60215172T2 (en) * 2001-07-06 2007-08-30 Neurosearch A/S NEW COMPOUNDS, THEIR PREPARATION AND USE
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
NZ536197A (en) * 2002-05-30 2006-08-31 Neurosearch As 3-substituted quinuclidines and their use
MXPA05001702A (en) * 2002-08-14 2005-04-19 Neurosearch As Novel quinuclidine derivatives and their use.
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ATE378048T1 (en) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res INHIBITION OF INFLAMMATION USING ALPHA-7 RECEPTOR-LINKING CHOLINERGIC AGONISTS
US7750022B2 (en) 2003-08-13 2010-07-06 Neurosearch A/S Quinuclidine derivatives and their pharmaceutical use
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
AU2005225458B2 (en) 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
SE0400970D0 (en) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
AU2005318225A1 (en) * 2004-12-22 2006-06-29 Neurosearch A/S Novel naphthyl substituted azabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DE602005025020D1 (en) 2004-12-27 2011-01-05 The Feinstein Inst Medical Res TREATMENT OF INFLAMMATORY DISEASES BY EL
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
WO2009150141A1 (en) * 2008-06-11 2009-12-17 Neurosearch A/S Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators
CN102215909B (en) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
PL3029039T3 (en) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
HK1208356A1 (en) 2012-05-08 2016-03-04 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSIMULATORS AND INDUCTIVE CHARGING SYSTEMS
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN113939334A (en) 2019-04-12 2022-01-14 赛博恩特医疗器械公司 Treatment of neurodegenerative disorders by vagal nerve stimulation
EP4566539A1 (en) 2020-05-21 2025-06-11 The Feinstein Institutes for Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315390B1 (en) 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
US5177084A (en) * 1989-08-08 1993-01-05 Merck Sharp & Dohme Ltd. Therapeutic use of substituted benzenes, formulations thereof and novel substituted benzenes
DE4009565A1 (en) * 1990-03-24 1991-09-26 Merck Patent Gmbh INDOLDER DERIVATIVES
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists

Also Published As

Publication number Publication date
WO2002044176A1 (en) 2002-06-06
EP1339712A1 (en) 2003-09-03
US20040044026A1 (en) 2004-03-04
JP2004514722A (en) 2004-05-20
US6884807B2 (en) 2005-04-26
DE60132710D1 (en) 2008-03-20
ATE385497T1 (en) 2008-02-15
DE60132710T2 (en) 2008-06-12
EP1339712B1 (en) 2008-02-06

Similar Documents

Publication Publication Date Title
AU2002220517A1 (en) 3-substituted quinuclidines and their use as nicotinic agonists
IL166254A0 (en) Novel quinuclidine derivatives and their use
PL375025A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
AU6583101A (en) Aryl and heteroaryl diazabicycloalkanes, their preparation and use
AU2003280309A1 (en) 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof
MXPA04010966A (en) Novel diazabicyclic biaryl derivatives.
IL186360A0 (en) Novel oxadiazole derivatives and their medical use
MXPA04000012A (en) Novel compounds, their preparation and use.
IL176260A0 (en) Diazabicyclic aryl derivatives as cholinergic receptor modulators
ATE289310T1 (en) HETEROARYL-DIAZABICYCLOACANDERIVATES AS CNS MODULATORS
MXPA05006861A (en) Novel diazabicyclic aryl derivatives.
MX2007004269A (en) Novel diazabicyclic aryl derivatives and their medical use.
WO2006087306A3 (en) Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors
EP1382605A3 (en) 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands
ATE334129T1 (en) 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE
WO2005111033A3 (en) Novel azabicyclic aryl derivatives
MXPA04010965A (en) Novel azacyclic ethynyl derivatives.
MX2007003331A (en) Novel diazabicyclic aryl derivatives as cholinergy ligands.
DE602004031124D1 (en) NEW CHINUCLIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
MXPA03007895A (en) Novel 2,5-diazabicyclo[2.2.1]heptane derivatives.
MX2007004245A (en) Novel azabicyclic aryl derivatives and their medical use.